EcoDrugPlus

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSVPAG00000009582
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSVPAG00000011066
Gene Symbol: RAF1
1 Cross references
216 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSVPAG00000007573
Gene Symbol: ROCK1
1 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSVPAG00000003665
Gene Symbol: ROCK2
1 Cross references
304 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSVPAG00000007949
Gene Symbol: TEK
1 Cross references
164 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSVPAG00000008128
Gene Symbol: TTK
1 Cross references
203 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSVPAG00000006133
Gene Symbol: UGCG
1 Cross references
211 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSVPAG00000005639
Gene Symbol: YES1
3 Cross references
269 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSVPAG00000001442
Gene Symbol: ACHE
1 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSVPAG00000007710
Gene Symbol: ACVRL1
1 Cross references
353 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSVPAG00000009827
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSVPAG00000000389
Gene Symbol: ADRB2
1 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).